Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor*

A model of the Ca2+-sensing receptor (CaSR) seven transmembrane domains was constructed based on the crystal structure of bovine rhodopsin. This model was used for docking (1S,2S,1′R)-N1-(4-chlorobenzoyl)-N2-[1-(1-naphthyl)ethyl]-1,2-diaminocyclohexane (Calhex 231), a novel potent negative allosteric modulator that blocks (IC50 = 0.39 μm) increases in [3H]inositol phosphates elicited by activating the human wild-type CaSR transiently expressed in HEK293 cells. In this model, Glu-8377.39 plays a pivotal role in anchoring the two nitrogen atoms of Calhex 231 and locating the aromatic moieties in two adjacent hydrophobic pockets delineated by transmembrane domains 3, 5, and 6 and transmembrane domains 1, 2, 3, and 7, respectively. To demonstrate its validity, we have mutated selected residues and analyzed the biochemical and pharmacological properties of the mutant receptors transfected in HEK293 cells. Two receptor mutations, F684A3.32 and E837A7.39, caused a loss of the ability of Calhex 231 to inhibit Ca2+-induced accumulation of [3H]inositol phosphates. Three other mutations, F688A3.36, W818A6.48, and I841A7.43, produced a marked increase in the IC50 of Calhex 231 for the Ca2+ response, whereas L776A5.42 and F821A6.51 led to a decrease in the IC50. Our data validate the proposed model for the allosteric interaction of Calhex 231 with the seven transmembrane domains of the CaSR. Interestingly, the residues at the same positions have been shown to delimit the antagonist-binding cavity of many diverse G-protein-coupled receptors. This study furthermore suggests that the crystal structure of bovine rhodopsin exhibits sufficient mimicry to the ground state of a very divergent class 3 receptor to predict the interaction of antagonists with the heptahelical bundle of diverse G-protein-coupled receptors.

[1]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[2]  C. Strader,et al.  Mutations that uncouple the beta-adrenergic receptor from Gs and increase agonist affinity. , 1987, The Journal of biological chemistry.

[3]  C. Strader,et al.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.

[4]  C. Strader,et al.  Allele-specific activation of genetically engineered receptors. , 1991, The Journal of biological chemistry.

[5]  S. Henikoff,et al.  Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.

[7]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[8]  E M Brown,et al.  Molecular Cloning and Functional Expression of Human Parathyroid Calcium Receptor cDNAs (*) , 1995, The Journal of Biological Chemistry.

[9]  S. Snyder,et al.  Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Park,et al.  Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Snyder,et al.  Cloned and Expressed Rat Ca-sensing Receptor , 1996, The Journal of Biological Chemistry.

[12]  A. Spiegel,et al.  The Carboxyl Terminus of the Human Calcium Receptor , 1997, The Journal of Biological Chemistry.

[13]  D. Gully,et al.  Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cells. , 1997, Biochemical and biophysical research communications.

[14]  Ajay N. Jain,et al.  Automatic identification and representation of protein binding sites for molecular docking , 1997, Protein science : a publication of the Protein Society.

[15]  J. Seidman,et al.  Amyloid‐β proteins activate Ca2+‐permeable channels through calcium‐sensing receptors , 1997 .

[16]  E. Brown,et al.  Extracellular calcium‐sensing receptor in rat oligodendrocytes: Expression and potential role in regulation of cellular proliferation and an outward K+ channel , 1998, Glia.

[17]  M F Balandrin,et al.  Calcimimetics with potent and selective activity on the parathyroid calcium receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Brown,et al.  Dimerization of the Extracellular Calcium-sensing Receptor (CaR) on the Cell Surface of CaR-transfected HEK293 Cells* , 1998, The Journal of Biological Chemistry.

[19]  R. Bukoski The perivascular sensory nerve Ca2+ receptor and blood pressure regulation: a hypothesis. , 1998, American journal of hypertension.

[20]  R. Simin,et al.  Domains determining ligand specificity for Ca2+ receptors. , 1999, Molecular pharmacology.

[21]  P. O'Hara,et al.  The Agonist-binding Domain of the Calcium-sensing Receptor Is Located at the Amino-terminal Domain* , 1999, The Journal of Biological Chemistry.

[22]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Stinnakre,et al.  Developmental and adult expression of rat calcium‐sensing receptor transcripts in neurons and oligodendrocytes , 2000, The European journal of neuroscience.

[24]  G. Hendy,et al.  Mutations of the calcium‐sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia , 2000, Human mutation.

[25]  M. Brann,et al.  Functional importance of the Ala(116)-Pro(136) region in the calcium-sensing receptor. Constitutive activity and inverse agonism in a family C G-protein-coupled receptor. , 2000, The Journal of biological chemistry.

[26]  P. Dauban,et al.  N1-Arylsulfonyl-N2-(1-aryl)ethyl-3-phenylpropane-1,2-diamines as novel calcimimetics acting on the calcium sensing receptor. , 2000, Bioorganic & medicinal chemistry letters.

[27]  Frank Diehl,et al.  Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists , 2000, The Journal of Biological Chemistry.

[28]  B. R. Smith,et al.  Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. , 2000, The Journal of clinical investigation.

[29]  N. Heveker,et al.  Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.

[30]  M. Ruat,et al.  High expression and anterograde axonal transport of aminoterminal sonic hedgehog in the adult hamster brain , 2001, The European journal of neuroscience.

[31]  J. Ballesteros,et al.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.

[32]  Didier Rognan,et al.  NMR-restrained docking of a peptidic inhibitor to the N-terminal domain of the phosphoenolpyruvate:sugar phosphotransferase enzyme I , 2001, J. Comput. Aided Mol. Des..

[33]  P. J. Steinbach,et al.  Human Ca(2+) receptor extracellular domain. Analysis of function of lobe I loop deletion mutants. , 2001, The Journal of biological chemistry.

[34]  E. Brown,et al.  Extracellular calcium sensing and extracellular calcium signaling. , 2001, Physiological reviews.

[35]  J. Gleason,et al.  Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. , 2001, The Journal of pharmacology and experimental therapeutics.

[36]  T K Attwood,et al.  A compendium of specific motifs for diagnosing GPCR subtypes. , 2001, Trends in pharmacological sciences.

[37]  D. Ward,et al.  Aminoglycoside antibiotics induce pH-sensitive activation of the calcium-sensing receptor. , 2002, Biochemical and biophysical research communications.

[38]  Harald Schwalbe,et al.  Editorial: Dissecting G‐Protein‐Coupled Receptors: Structure, Function, and Ligand Interaction , 2002, Chembiochem : a European journal of chemical biology.

[39]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[40]  K. Jacobson,et al.  Identification of Acidic Residues in the Extracellular Loops of the Seven-transmembrane Domain of the Human Ca2+ Receptor Critical for Response to Ca2+ and a Positive Allosteric Modulator* , 2002, The Journal of Biological Chemistry.

[41]  J. Northup,et al.  Evidence for Distinct Cation and Calcimimetic Compound (NPS 568) Recognition Domains in the Transmembrane Regions of the Human Ca2+ Receptor* , 2002, The Journal of Biological Chemistry.

[42]  E. Nemeth,et al.  The search for calcium receptor antagonists (calcilytics). , 2002, Journal of molecular endocrinology.

[43]  Didier Rognan,et al.  Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.

[44]  Ajay N. Jain Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[45]  S. Nakanishi,et al.  Structure of the metabotropic glutamate receptor , 2003, Current Opinion in Neurobiology.

[46]  J. Kew,et al.  Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.

[47]  L. Prézeau,et al.  Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. , 2003, Pharmacology & therapeutics.